Skip to main content

Table 4 Associations between laboratory TLS and bortezomib-containing therapy in patients with multiple myeloma by sex (multivariate analysis)

From: Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study

 

No. of patients with TLS/total No. (%)

OR (95% CI)

P-value

Female (n = 108)

 Therapy without bortezomib

2/42 (4.8)

1.00

(reference)

 

 Bortezomib-containing therapy

3/66 (4.5)

0.77

(0.09–6.10)

0.804 a

Male (n = 102)

 Therapy without bortezomib

1/38 (2.6)

1.00

(reference)

 

 Bortezomib-containing therapy

11/64 (17.2)

8.51

(1.04–69.60)

0.046 a

  1. TLS Tumor lysis syndrome, OR Odds ratio, CI Confidence interval
  2. a Multivariable adjusted for ISS stage 3, pretreatment serum creatinine level (> upper limit of normal range), and pretreatment serum uric acid level (> upper limit of normal range)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us